Alimera makes deal with Emory

Article

Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.

Alimera Sciences has entered into an exclusive worldwide agreement with Emory University, USA to explore oxidative stress management as a treatment for ophthalmic diseases.

The agreement gives Alimera the exclusive option to license a unique class of compounds, NADPH (nicotinamide adenine dinucleotide phosphate reduced form) oxidise inhibitors, as a potential treatment for conditions such as dry age-related macular degeneration (AMD).

Alimera will also receive the exclusive rights to sublicense in ophthalmology and the exclusive rights for non-ophthalmic use. The company will be responsible for the development and commercialization of the compounds and Emory will receive milestone payments and royalties from net sales.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.